ELITE PHARMACEUTICALS INC /NV/ Quarterly Operating Income (Loss) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Operating Income (Loss) for the quarter ending September 30, 2024 was $3.48M, a 81% increase year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ Operating Income (Loss) for the twelve months ending September 30, 2024 was $14.6M, a 186% increase year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ annual Operating Income (Loss) for 2023 was $10.8M, a 193% increase from 2022.
  • Elite Pharmaceuticals Inc /Nv/ annual Operating Income (Loss) for 2022 was $3.68M, a 27.5% decline from 2021.
  • Elite Pharmaceuticals Inc /Nv/ annual Operating Income (Loss) for 2021 was $5.07M, a 141% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $14.6M $3.48M +$1.56M +81% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $13.1M $3.86M +$2.26M +141% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $10.8M $3.73M +$4.12M Jan 1, 2024 Mar 31, 2024 10-K 2024-07-01
Q4 2023 $6.67M $3.53M +$1.57M +80.3% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $5.1M $1.93M +$844K +78.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $4.26M $1.6M +$579K +56.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $3.68M -$387K -$1.24M -145% Jan 1, 2023 Mar 31, 2023 10-K 2024-07-01
Q4 2022 $4.91M $1.96M +$128K +6.98% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $4.79M $1.08M -$341K -24% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $5.13M $1.02M +$57.5K +5.96% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $5.07M $852K +$1.92M Jan 1, 2022 Mar 31, 2022 10-K 2023-06-29
Q4 2021 $3.15M $1.83M +$830K +82.9% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 $2.32M $1.42M +$82.3K +6.14% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $2.24M $965K +$135K +16.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $2.1M -$1.07M +$307K +22.3% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-29
Q4 2020 $1.8M $1M +$310K +44.8% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $1.49M $1.34M +$1.79M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$307K $831K +$1.98M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$2.29M -$1.37M +$636K +31.6% Jan 1, 2020 Mar 31, 2020 10-K 2021-06-14
Q4 2019 -$2.92M $691K +$3.33M Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 -$6.25M -$455K +$2.2M +82.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$8.45M -$1.15M +$711K +38.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$9.16M -$2.01M +$613K +23.4% Jan 1, 2019 Mar 31, 2019 10-K 2020-06-30
Q4 2018 -$9.77M -$2.64M -$578K -28.1% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 -$9.19M -$2.65M -$523K -24.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$8.67M -$1.86M +$380K +17% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$9.05M -$2.62M +$567K +17.8% Jan 1, 2018 Mar 31, 2018 10-K 2018-06-14
Q4 2017 -$9.62M -$2.06M -$337K -19.6% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-11
Q3 2017 -$9.28M -$2.13M -$925K -76.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$8.36M -$2.24M -$1M -80.8% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$7.36M -$3.19M -$3.76M -659% Jan 1, 2017 Mar 31, 2017 10-K 2018-06-14
Q4 2016 -$3.59M -$1.72M +$991K +36.5% Oct 1, 2016 Dec 31, 2016 10-K 2018-06-14
Q3 2016 -$4.59M -$1.21M +$2.56M +68% Jul 1, 2016 Sep 30, 2016 10-K 2018-06-14
Q2 2016 -$7.15M -$1.24M +$1.17M +48.6% Apr 1, 2016 Jun 30, 2016 10-K 2018-06-14
Q1 2016 -$8.32M $571K +$6.03M Jan 1, 2016 Mar 31, 2016 10-K 2018-06-14
Q4 2015 -$14.3M -$2.71M -$156K -6.1% Oct 1, 2015 Dec 31, 2015 10-K 2018-06-14
Q3 2015 -$14.2M -$3.77M +$294K +7.24% Jul 1, 2015 Sep 30, 2015 10-K 2018-06-14
Q2 2015 -$14.5M -$2.41M +$2.02M +45.7% Apr 1, 2015 Jun 30, 2015 10-K 2018-06-14
Q1 2015 -$16.5M -$5.46M -$3.07M -129% Jan 1, 2015 Mar 31, 2015 10-K 2017-06-14
Q4 2014 -$13.4M -$2.56M -$1.32M -107% Oct 1, 2014 Dec 31, 2014 10-K 2017-06-14
Q3 2014 -$12.1M -$4.06M -$3.37M -491% Jul 1, 2014 Sep 30, 2014 10-K 2017-06-14
Q2 2014 -$8.74M -$4.43M -$3.46M -354% Apr 1, 2014 Jun 30, 2014 10-K 2017-06-14
Q1 2014 -$5.28M -$2.38M -$2.1M -728% Jan 1, 2014 Mar 31, 2014 10-K 2016-06-15
Q4 2013 -$3.19M -$1.24M -$963K -351% Oct 1, 2013 Dec 31, 2013 10-K 2016-06-15
Q3 2013 -$2.23M -$687K -$172K -33.3% Jul 1, 2013 Sep 30, 2013 10-K 2016-06-15
Q2 2013 -$2.05M -$976K -$490K -101% Apr 1, 2013 Jun 30, 2013 10-K 2016-06-15
Q1 2013 -$1.56M -$288K +$319K +52.6% Jan 1, 2013 Mar 31, 2013 10-K 2014-06-30
Q4 2012 -$1.88M -$274K +$157K +36.4% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-14
Q3 2012 -$2.04M -$515K +$76.3K +12.9% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-14
Q2 2012 -$2.12M -$486K -$149K -44.3% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 -$1.97M -$607K +$118K +16.3% Jan 1, 2012 Mar 31, 2012 10-K 2013-06-21
Q4 2011 -$2.08M -$431K -$504K -691% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-14
Q3 2011 -$1.58M -$592K -$455K -332% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 -$1.13M -$337K -$240K -248% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q1 2011 -$886K -$725K Jan 1, 2011 Mar 31, 2011 10-K 2012-06-29
Q4 2010 $72.9K Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-14
Q3 2010 -$137K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 -$96.8K Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-08-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.